Stock · EUZ.DE · Healthcare
Germany · Small Cap · Revenue 12 mo. €312.5M
Price as of 11/06/2026
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally.
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
Original text from the data provider
Summary
51.0 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €34.4M (2025), it supports €382.1M. The remaining €494.6M of the market value assume it grows 11.6% a year for 10 years and not at all afterwards.
Required FCF growth per year
11.6%
no growth afterwards
Price to operating cash flow 16.8×, within its usual range.
Middle half of 20 quarters: 15.5× to 23.0×, median 17.6×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 19.37% | 11.52% | Rank 77 |
| Return on capital (Greenblatt) | 24.08% | 32.55% | Rank 33 |
| EBIT margin | 24.06% | 18.31% | Rank 71 |
| FCF margin | 11.02% | 14.12% | Rank 36 |
| Gross margin | 47.19% | 60.99% | Rank 32 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 5.45% | 8.04% | Rank 36 |
| Earnings growth, 3 years per year | 18.28% | 5.44% | Rank 74 |
| Earnings growth, 5 years per year | 17.70% | 7.00% | Rank 78 |
| Sustainable growth (ROE × retained earnings) | 8.34% | 3.66% | Rank 90 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 5.63% | 2.90% | Rank 84 |
| FCF yield | 3.92% | 3.63% | Rank 52 |
| EV/saleslower is better | 2.54 | 4.03 | Rank 67 |
| EV/EBITlower is better | 10.56 | 21.73 | Rank 94 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −22.76% | 8.66% | Rank 14 |
| Share price, 6 months | −9.20% | 24.27% | Rank 5 |
| Share price, 3 months | 4.41% | 15.42% | Rank 25 |
| Distance from 52-week high | −18.10% | −7.35% | Rank 23 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 3.08% | 0.30% | Rank 27 |
| Change in share countlower is better | 0.39% | 0.00% | Rank 22 |
| Dividend streak in years | 1 | 10 | Rank 29 |
| Price reaction to results, market-adjusted | −0.30% | 0.05% | Rank 45 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 51.84% | 48.40% | Rank 55 |
| Net debt/EBITDAlower is better | −0.91 | 1.11 | Rank 82 |
| Debt to equitylower is better | 0.18 | 0.48 | Rank 74 |
| Volatility, 1 yearlower is better | 31.74% | 31.42% | Rank 48 |
Ten years in figures
| Year | Revenue, €M | EBIT margin | FCF, €M | Shares | Net debt, €M |
|---|---|---|---|---|---|
| 2016 | 137.9 | 11.1% | 14.5 | 63.5M | −24.9 |
| 2017 | 138.6 | 13.8% | 22.7 | 63.5M | −56.0 |
| 2018 | 168.7 | 13.7% | 15.1 | 62.0M | −54.1 |
| 2019 | 178.5 | 17.7% | 33.2 | 61.6M | −59.0 |
| 2020 | 176.1 | 20.0% | 27.9 | 61.9M | −67.1 |
| 2021 | 180.4 | 25.5% | 5.0 | 62.3M | −66.7 |
| 2022 | 222.3 | 21.1% | 3.2 | 62.4M | −33.1 |
| 2023 | 246.1 | 19.1% | 21.1 | 62.5M | −11.7 |
| 2024 | 295.9 | 20.6% | 49.4 | 62.6M | −62.9 |
| 2025 | 312.0 | 24.1% | 34.4 | 62.8M | −83.9 |
3 of 7 StockScorer Score rules met · How the score is built
Eckert & Ziegler Strahlen- und Medizintechnik AG mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Eckert & Ziegler Strahlen- und Medizintechnik AG is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
4 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Eckert & Ziegler Strahlen- und Medizintechnik AG.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 17.8 | 30.0 |
| P/B ratio | 3.4 | 4.8 |
| Return on equity (ROE) | 19.4% | 11.5% |
| Equity ratio | 51.8% | 48.4% |
| Debt-to-equity (D/E) | 0.18 | 0.48 |
| Dividend yield | 1.6% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| EUZ.DE | Eckert & Ziegler Strahlen- und Medizintechnik AGthis page | |
| DRW3.DE | Drägerwerk AG & Co. KGaA (pref) | Low2.7 |
| PODD | Insulet Corporation | Medium5.5 |
| DEMANT.CO | Demant A/S | locked |
| 7733.T | Olympus Corp. | locked |
| SN.L | Smith & Nephew PLC | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.